» Articles » PMID: 37070448

Emerging Treatment Approaches for COVID-19 Infection: A Critical Review

Overview
Journal Curr Mol Med
Specialty Molecular Biology
Date 2023 Apr 18
PMID 37070448
Authors
Affiliations
Soon will be listed here.
Abstract

In the present scenario, the SARS-CoV-2 virus has imposed enormous damage on human survival and the global financial system. It has been estimated that around 111 million people all around the world have been infected, and about 2.47 million people died due to this pandemic. The major symptoms were sneezing, coughing, cold, difficulty breathing, pneumonia, and multi-organ failure associated 1with SARS-CoV-2. Currently, two key problems, namely insufficient attempts to develop drugs against SARSCoV-2 and the lack of any biological regulating process, are mostly responsible for the havoc caused by this virus. Henceforth, developing a few novel drugs is urgently required to cure this pandemic. It has been noticed that the pathogenesis of COVID-19 is caused by two main events: infection and immune deficiency, that occur during the pathological process. Antiviral medication can treat both the virus and the host cells. Therefore, in the present review, the major approaches for the treatment have been divided into "target virus" and "target host" groups. These two mechanisms primarily rely on drug repositioning, novel approaches, and possible targets. Initially, we discussed the traditional drugs per the physicians' recommendations. Moreover, such therapeutics have no potential to fight against COVID-19. After that, detailed investigation and analysis were conducted to find some novel vaccines and monoclonal antibodies and conduct a few clinical trials to check their effectiveness against SARSCoV- 2 and mutant strains. Additionally, this study presents the most successful methods for its treatment, including combinatorial therapy. Nanotechnology was studied to build efficient nanocarriers to overcome the traditional constraints of antiviral and biological therapies.

References
1.
Puelles V, Lutgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L . Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592. PMC: 7240771. DOI: 10.1056/NEJMc2011400. View

2.
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M . The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020; 53:25-32. PMC: 7211650. DOI: 10.1016/j.cytogfr.2020.05.003. View

3.
Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

4.
Iacob S, Iacob D . SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. Front Pharmacol. 2020; 11:1224. PMC: 7479232. DOI: 10.3389/fphar.2020.01224. View

5.
Hillen H . Structure and function of SARS-CoV-2 polymerase. Curr Opin Virol. 2021; 48:82-90. PMC: 8023233. DOI: 10.1016/j.coviro.2021.03.010. View